Tag: Liver
FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer
The CheckMate-9DW trial showed significant overall survival benefit versus lenvatinib or sorafenib
Statins May Reduce Risk for Hepatocellular Carcinoma in Chronic Liver Disease
Improved Fibrosis-4 group transitions seen over time for patients with chronic liver disease using statins
Dose-Dependent Link Seen for Alcohol, Cirrhosis, Liver Cancer in Patients With Hep B
Each daily consumption of 12 g alcohol increases risk for cirrhosis by 6.2 percent, hepatocellular carcinoma by 11.5 percent
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab
PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis
Model accurately predicts hepatocellular carcinoma among patients with HCV-related cirrhosis with SVR to DAAs
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
New model exhibited satisfactory discrimination and calibration, with c-statistics of 0.844 and 0.813 in derivation, validation cohorts
Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
Improvement in hepatic pain seen in 67 percent of patients receiving radiotherapy plus best supportive care
Women With Liver Cancer Less Likely Than Men to Receive Liver Transplant
Furthermore, women are more likely to die waiting for a donor liver than men
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
Age and immune checkpoint inhibitor washout time inversely linked to allograft rejection; survival no different with, without allograft rejection
